4.6 Editorial Material

Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers

Related references

Note: Only part of the references are listed.
Article Oncology

Is patient travel distance associated with survival on phase II clinical trials in oncology?

EB Lamont et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)